We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Considerations for Submitting Impurity Data as ANDA Approvals Drop in January
FDA Issues Considerations for Submitting Impurity Data as ANDA Approvals Drop in January
The FDA released new information for ANDA applicants on when to submit elemental impurity data, and acknowledged that new guidelines on reporting elemental impurities had slowed approvals in January.